Complement-binding anti-HLA antibodies and kidney-allograft survival

Area of Science:

• Nephrology
• Immunology
• Transplantation Science

Background:

• Anti-HLA antibodies are a major barrier to successful kidney transplantation.
• Complement cascade activation plays a key role in antibody-mediated rejection.
• The complement-binding capacity of anti-HLA antibodies may influence kidney allograft failure.

Purpose of the Study:

• To investigate the role of complement-binding capacity of donor-specific anti-HLA antibodies in kidney-allograft failure.
• To determine if this capacity can predict graft loss.

Main Methods:

• A population-based study of 1016 kidney allograft recipients in Paris (2005-2011).
• Screening for circulating donor-specific anti-HLA antibodies and their complement-binding capacity.
• Assessment of graft injury phenotype and time to kidney-allograft loss.

Main Results:

• Patients with complement-binding donor-specific anti-HLA antibodies had a significantly lower 5-year graft survival rate (54%) compared to non-complement-binding (93%) or no donor-specific anti-HLA antibodies (94%).
• Complement-binding antibodies were associated with a >4-fold increased risk of graft loss, independent of other factors.
• These antibodies correlated with increased antibody-mediated rejection, severe graft injury, and C4d deposition.

Conclusions:

• Assessing the complement-binding capacity of donor-specific anti-HLA antibodies is valuable for identifying kidney transplant recipients at high risk of graft loss.
• This assessment can improve risk stratification and potentially guide preemptive treatment strategies.